ArticleScientific reports2020
Disease progression modeling of Alzheimer's disease according to education level.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The impact of slope-adjusted visit-to-visit body mass index variability on early dementia risk prediction.International journal of obesity (2005) · 2026Article
- Visit-to-visit blood pressure variability and dementia risk after considering antihypertensive treatment: real-world data from the Japanese National Health Insurance.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Ethnic differences in the prevalence of amyloid positivity and cognitive trajectories.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD): A Cohort for Dementia Research and Ethnic-Specific Insights.Dementia and neurocognitive disorders · 2024Article
- Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Risk of cognitive decline progression is associated to increased blood-brain-barrier permeability: A longitudinal study in a memory unit clinical cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- The QPLEX™ Plus Assay Kit for the Early Clinical Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2023Article
- Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.CPT: pharmacometrics & systems pharmacology · 2023Observational
- Characteristics and Predictors of Alzheimer's Disease Resilience Phenotype.Journal of clinical medicine · 2023Article
- Role of Disease Progression Models in Drug Development.Pharmaceutical research · 2022Review
- Cortical thickness is differently associated with ALDH2 rs671 polymorphism according to level of amyloid deposition.Scientific reports · 2021Article
- Dual-Task Tests Predict Conversion to Dementia-A Prospective Memory-Clinic-Based Cohort Study.International journal of environmental research and public health · 2020Article
- Simulation of long-term lecanemab treatment effect on Alzheimer's disease progression.Alzheimer's & dementia (New York, N. Y.)Article
- Disease progression from mild cognitive impairment to dementia for patients with Alzheimer's disease or Lewy body pathology.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop a disease progression model of Alzheimer's disease (AD) that shows cognitive decline from subjective cognitive impairments (SCI) to the end stage of AD dementia (ADD) and to investigate the effect of education level on the whole disease spectrum, we enrolled 565 patients who were followed up more than three times and had a clinical dementia rating sum of boxes (CDR-SB). Three cohorts, SCI (n = 85), amnestic mild cognitive impairment (AMCI, n = 240), and ADD (n = 240), were overlapped in two consecutive cohorts (SCI and AMCI, AMCI and ADD) to construct a model of disease course, and a model with multiple single-cohorts was estimated using a mixed-effect model. To examine the effect of education level on disease progression, the disease progression model was developed with data from lower (≤ 12) and higher (> 12) education groups. Disease progression takes 274.3 months (22.9 years) to advance from 0 to 18 points using the CDR-SB. Based on our predictive equation, it takes 116.5 months to progress from SCI to AMCI and 56.2 months to progress from AMCI to ADD. The rate of CDR-SB progression was different according to education level. The lower-education group showed faster CDR-SB progression from SCI to AMCI compared to the higher-education group, and this trend disappeared from AMCI to ADD. In the present study, we developed a disease progression model of AD spectrum from SCI to the end stage of ADD. Our disease modeling provides us with more understanding of the effect of education on cognitive trajectories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.